Welcome to our dedicated page for Microbot Med news (Ticker: MBOT), a resource for investors and traders seeking the latest updates and insights on Microbot Med stock.
Microbot Medical Inc (NASDAQ: MBOT) is a pioneer in micro-robotic medical technologies focused on revolutionizing minimally invasive procedures. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's progress in developing autonomous surgical platforms like the LIBERTY Robotic System and Self-Cleaning Shunt technology.
Discover comprehensive coverage of MBOT's latest press releases, including clinical milestones, regulatory updates, and strategic partnerships. Our curated news collection serves as a centralized resource for tracking advancements in robotic-assisted interventions designed to reduce surgical trauma and improve patient outcomes.
Key updates include developments in patented micro-robotic platforms, financial performance reports, and innovations addressing complex surgical challenges. Bookmark this page to stay informed about MBOT's progress in creating next-generation tools that aim to transform vascular and endoscopic procedures through precision robotics.
Microbot Medical (Nasdaq: MBOT) has announced a strategic collaboration with Stryker’s Neurovascular division to integrate its neurovascular instruments with the LIBERTY Robotic System. This partnership aims to create the first dedicated robotic procedural kits for specific neurovascular procedures, enhancing the competitive edge of the LIBERTY system. The company will maintain independent development for the LIBERTY system in peripheral and coronary procedures. Animal studies suggest this innovation could enable safer, more efficient remote catheter-based procedures, potentially reducing risks for healthcare professionals.
Microbot Medical (Nasdaq: MBOT) announced the issuance of a Notice of Allowance for a third patent related to its LIBERTY® Robotic System by the USPTO. In 2021, the company secured three U.S. patents, bringing its total to 47 patents issued or allowed worldwide, with an additional 26 pending applications. CEO Harel Gadot stated that this year has been crucial for the LIBERTY system, highlighting the ongoing progress in IP and R&D. The granted claims protect a compact robotic device for surgical tool manipulation, reinforcing the company’s confidence in achieving its clinical goals for 2022.
Microbot Medical (Nasdaq: MBOT) is advancing the LIBERTY® Robotic System toward commercialization. Following a recent design freeze, Dr. Eyal Morag visited the U.S. to set up clinical infrastructure for an upcoming human trial expected to begin in late 2022. Dr. Morag emphasized the importance of aligning interests for key milestones, including an FDA pre-submission and the clinical trial. This marks a pivotal moment in advancing LIBERTY’s development, which aims to enhance clinical outcomes through innovative micro-robotic technologies.
Microbot Medical Inc. (MBOT) has achieved a significant milestone by reaching the design freeze for its LIBERTY Robotic System, marking a step towards commercialization. This milestone is based on extensive feasibility studies and physician feedback. The next step involves filing a pre-submission with the FDA in Q1 2022. A live demonstration of the LIBERTY System is scheduled for January 10th, 2022, in San Francisco. The company expresses confidence in advancing towards commercialization and aims to secure clinical sites for regulatory compliance.
Microbot Medical Inc. (Nasdaq: MBOT) announced a Notice of Allowance for a second patent regarding its LIBERTY® Robotic System from the USPTO. This brings the company's total to 46 patents issued/allowed and 24 pending applications. CEO Harel Gadot highlighted that the U.S. market is critical for LIBERTY® and emphasized the importance of protecting their intellectual property for future commercialization and shareholder value. The patent covers a modular robotic system for manipulating flexible surgical tools, enhancing innovation in medical devices.
Microbot Medical Inc. (Nasdaq: MBOT) announced the issuance of a Notice of Allowance for its LIBERTY® Robotic System by the USPTO, marking a significant milestone in its intellectual property portfolio, which now consists of 45 patents issued/allowed and 24 pending applications. CEO Harel Gadot emphasized this achievement as crucial for securing a competitive edge and advancing commercialization of their technology aimed at enhancing catheter-based procedures while minimizing risks for physicians. The patent covers a device designed to automate the manipulation of surgical tools within bodily lumens.
Microbot Medical (Nasdaq: MBOT) announced a Notice of Allowance (NOA) for its 'One & Done' guidewire technology in China, adding to previous approvals in the European Union, Japan, and Israel. With a total of 44 patents allowed or issued and 24 pending globally, the company aims to enhance patient outcomes and strengthen its competitive position. The double guidewire technology includes features for adjusting curvature and stiffness, indicating advancements in micro-robotic applications for healthcare.
Microbot Medical (NASDAQ: MBOT) has strengthened its Scientific Advisory Board with the addition of Dr. Giora Weisz, a renowned interventional cardiologist. Dr. Weisz's extensive experience in robotic-enhanced coronary interventions, particularly his role in the FDA-approved CorePath system, is expected to aid Microbot in advancing its LIBERTY Robotic System. CEO Harel Gadot emphasized the significance of Dr. Weisz's involvement in enhancing the system to address the growing cardiac market. Microbot specializes in micro-robotic technologies aimed at improving patient outcomes.
Microbot Medical Inc. (Nasdaq: MBOT) has received a Notice of Allowance from the Israel Intellectual Property Office for its innovative 'One & Done' guidewire technology. This patent joins previously granted approvals in Europe and Japan, enhancing Microbot's global patent portfolio to 42 issued/allowed patents and 23 pending applications. CEO Harel Gadot emphasized the importance of this technology for the company's future development and competitive edge in the micro-robotic medical field.
Microbot Medical Inc. (Nasdaq: MBOT) has been notified by the Japan Patent Office (JPO) that it intends to grant a patent for its innovative ‘One & Done’ guidewire technology aimed at endoluminal interventions. This marks Japan as the second jurisdiction to recognize this patent, enhancing the company’s intellectual property protection. CEO Harel Gadot highlighted the positive feedback from the medical community regarding their LIBERTY™ Robotic system and noted that the allowed claims cover a dual guidewire structure with adjustable states. Currently, Microbot holds 41 issued patents and has 22 pending applications.
FAQ
What is the current stock price of Microbot Med (MBOT)?
What is the market cap of Microbot Med (MBOT)?
